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Abstract Heparin is a well-known glycosaminoglycan
extracted from porcine intestines. Increased vigilance for
transmissible spongiform encephalopathy in animal-derived
pharmaceuticals requires methods to prevent the introduc-
tion of heparin from ruminants into the supply chain. The
sensitivity, specificity, and precision of the quantitative
polymerase chain reaction (PCR) make it a superior
analytical platform for screening heparin raw material for
bovine-, ovine-, and caprine-derived material. A quantita-
tive PCR probe and primer set homologous to the ruminant
Bov-A2 short interspersed nuclear element (SINE) locus
(Mendoza-Romero et al. J. Food Prot. 67:550–554, 2004)
demonstrated nearly equivalent affinities for bovine, ovine,
and caprine DNA targets, while exhibiting no cross-
reactivity with porcine DNA in the quantitative PCR
method. A second PCR primer and probe set, specific for
the porcine PRE1 SINE sequence, was also developed to
quantify the background porcine DNA level. DNA extrac-
tion and purification was not necessary for analysis of the
raw heparin samples, although digestion of the sample with
heparinase was employed. The method exhibits a quantita-
tion range of 0.3–3,000 ppm ruminant DNA in heparin.
Validation parameters of the method included accuracy,
repeatability, precision, specificity, range, quantitation limit,
and linearity.
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Introduction
Heparin is a sulfated polysaccharide that has been used
clinically as an anticoagulant for many years. It is
composed of alternating 1 → 4 linked residues of uronic
acid and glucosamine with various levels of sulfation.
Heparin can be found in a many tissues (e.g., lung,
intestines, liver, skin) from a number of animal species
(e.g., ox, dog, chicken, sheep, whale) [1]. Porcine intestines
are the most significant source of heparin currently used in
clinical applications. The concern with disease transmis-
sion, most notably prions associated with transmissible
spongiform encephalopathy from ruminant tissues [2],
makes it necessary to ensure that the supply chain for
animal-derived pharmaceuticals is monitored with regard to
the source of the material. The possibility of comingling
tissue of other animal species such as bovine (cattle), ovine
(sheep), and caprine (goat) at multi-product-processing sites
creates the need for analytical methods that can distinguish
the source of raw heparin.
The detection of ruminant material in animal-derived
materials has been extensively described [3–8]. These
detection methods include immunological, microscopic,
spectroscopic, and nucleic acid detection techniques.
Microscopic and spectroscopic analytical methods lack
sensitivity, with detection limits as high as 1% and the
potential for inaccurate results. Although ELISA offers
improved sensitivity, with detection limits as low as 0.01%,
this platform can exhibit poor accuracy owing to matrix
interferences, false positives from cross-reactivity, and poor
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none of these technologies can be used to determine if
chemical or biological adulterants have been added to the
crude heparin material to mask the source. In contrast,
nucleic acid detection, in general, and quantitative poly-
merase chain reaction (PCR), in particular, offer significant
advantages in sensitivity, specificity, accuracy, and robust-
ness [9, 10]. Heparin-mediated inhibition of PCR has been
previously described and requires particular precautions to
ensure accurate detection and measurement of target
sequences [11]. The use of heparinase to degrade the
heparin present in the sample is one technique to overcome
heparin-mediated quantitative PCR inhibition, and the
inclusion of a ruminant spike prior to heparinase digestion
ensures accurate quantitation. A quantitative PCR analytical
method was developed, validated, and is in current use to
assess the animal origin of commercially available crude
heparin.
Materials and methods
Materials and equipment
The PCR instrument used in this study was an ABI Prism
7900HT sequence detection system (Applied Biosystems,
Foster City, CA, USA). Quantitative PCR requires the use
of DNA primers and probes to amplify the target DNA if
present. Primers and internal probes specific for short
interspersed nuclear elements (SINEs) present in both the
ruminant and the porcine genomes were used to detect
ruminant DNA in crude heparin as well as to verify the
presence of porcine DNA in this material. SINEs were
selected as the target DNA owing to their abundant copy
number in genomes and the consequent high level of
sensitivity and specificity which they offers [12]. The
ruminant Bov-A2 SINE consensus sequence has been
previously described [9] and exhibits broad specificity
across bovine, ovine, and caprine genomes. The absence
of detectable levels of porcine DNA suggests either
chemical or biological adulteration of the crude heparin.
Therefore, primers and an internal probe corresponding to
the porcine PRE1 SINE sequence were designed by
Applied Biosystems and used in the assay and validation
described. All primers and probes used in the analysis are
shown in Figs. 1 and 2.
Commercially available bovine DNA (part no. 69231,
EMD Chemicals, Gibbstown, NJ, USA) was used to
prepare the ruminant DNA reference solutions used for
quantitation. Commercially available porcine DNA (part
no. 69230, EMD Chemicals, Gibbstown, NJ, USA) was
used to prepare the porcine DNA reference solutions.
Commercially available ovine DNA (part no. GSHE,
Zyagen, San Diego, CA, USA) was solubilized in molec-
ular biology grade water and used to verify the specificity
of the ruminant and porcine primers and probes. Caprine
DNA was prepared by weighing 485 mg of goat meat in a
15-mL sterile tube, adding 6 mL of nuclei lysis solution
(Wizard genomic DNA purification kit, part no. A1120,
Promega, Madison, WI, USA), and macerating the sample
for 10 min. The sample was incubated for 30 min at 65 °C.
The tissue debris was removed by centrifugation and 600
μL of the supernatant was removed. The caprine DNA was
purified from the supernatant following the kit instructions
and was used to determine the specificity of the ruminant
and porcine primers and probes. The concentration and
purity of the ovine and caprine DNA solutions were
determined from the absorbance at 260, 280, and 320 nm.
Sample, standard, and spike preparation
Crude heparin samples for analysis were prepared by
weighing approximately 300 mg crude heparin into a sterile
tube. Ten milliliters of 50 mM tris(hydroxymethyl)amino-
methane–HCl/5 mM CaCl2 (pH 8.0), which is referred to as
heparinase digestion buffer, was added and the sample was
mixed vigorously to dissolve the solids. The dissolved
sample was diluted 1:99 with heparinase digestion buffer to
create a 0.03% (w/v) working crude heparin solution.
Standard curves were created by adding appropriate
volumes of each reference DNA solution (porcine, bovine,
ovine, or caprine) in heparinase digestion buffer to achieve
concentrations of 0.1, 1, 10, 100, and 1,000 pg DNA/μL.
An additional standard at 2,000 pg DNA/μL was included
for the porcine DNA assay to accommodate the high
concentration of host DNA in crude heparin.
Control samples included a solution of each 0.03% crude
heparin sample spiked with 200 pg DNA/μL, a sample of
Forward primer: 5’-GAC TGA GCG ACT TCA CTT TCA 
Reverse primer: 5’-GGA TTC TCC AGG CAA GAA CA 
Internal probe: 5’-FAM-TTG GAG AAG GAA ATC GCA ACC CAC TCC-TAMRA 
Fig. 1 Ruminant primers and probe
758 S.P. Concannon et al.heparinase digestion buffer spiked with 200 pg DNA/μL,
and a sentinel negative control of unspiked heparinase
digestion buffer. All controls and standards were
heparinase-digested and analyzed in parallel with each test
article. Additionally, nontemplate controls (NTCs) were
included with the amplification phase of the method.
DNAse inactivation and heparinase digestion
All standard curve dilutions, test articles, and control
samples were incubated at 80±5 °C for 5±1 min to
inactivate any DNase that may be present and were
subsequently placed on ice for a minimum of 10 min.
Two units of heparinase I (product no. H2519, Sigma-
Aldrich, St. Louis, MO, USA) was added to each standard
curve dilution, test article, and control prior to incubation
for 18±0.5 h at 28±2 °C.
Quantitative PCR amplification
The heparinase-treated materials were subjected to quanti-
tative PCR using the TaqMan universal PCR master mix
chemistry and the species-specific DNA primers and
probes. All standards, test articles, and controls were
analyzed in triplicate. System suitability criteria applied to
the analytical method included a standard curve coefficient
of determination (R
2) of 0.9 or greater, a slope of -4.0 or
greater, recovery of ±0.6 log of the 200 pg DNA/μL spike
in the test article, relative standard deviation (RSD) of the
threshold cycle (CT) for replicates of 10% or less, and a
verification that the mean CT of the sentinel negative
control and NTC were both greater than the mean CT of the
lowest standard curve sample.
Results
Specificity
A standard curve of ovine DNA was prepared in heparinase
digestion buffer at concentrations of 0.01, 0.1, 1, 10, 100,
and 1,000 pg/μL and analyzed using the ruminant DNA
primers and probe. Statistical and visual analysis of the
response obtained with the 0.01 pg/μL standard found that
this ovine DNA concentration could not be distinguished
from the background response of the NTC and was below
the quantitation limit of the method. Exclusion of the
0.01 pg/μL standard yielded a standard curve with an R
2 of
0.99 and a slope of -2.79, with an amplification efficiency
of 128%. Therefore, it was concluded that the ruminant
primers and probe can be used to quantitate also ovine
DNA in solution at concentrations greater than 0.1 pg/μL.
A standard curve of caprine DNAwas similarly prepared
in heparinase digestion buffer at concentrations of 0.1, 1,
10, 100, and 1,000 pg/μL and was analyzed using the
ruminant DNA primers and probe set. The 0.1 pg/μL
response was indistinguishable from the background
response of the NTC and was determined to be below the
quantitation limit. When the 0.1 pg/μL standard was
removed from the analysis, the standard curve exhibited
an R
2 of 0.99 and a slope of -3.2, corresponding to an
amplification efficiency of 105%. Therefore, the ruminant
primers and probe can be used to quantitate caprine DNA in
solution at concentrations greater than 1 pg/μL.
Porcine DNA at a concentration of 1,000 pg/μLi n
heparinase digestion buffer was indistinguishable from the
response of the background (NTC) and sentinel extraction
control (SEC) when analyzed with the ruminant primers
and probe. An analogous assessment of ruminant DNA at a
concentration of 1,000 pg/μL in heparinase digestion buffer
was indistinguishable from the response of both the NTC
and the SEC when tested with the porcine primers and
probe.
Linearity
The ruminant DNA standard curve was prepared as
described in “Materials and methods” and analyzed using
the ruminant primers and probe set on four separate
occasions. The standard curve was created by plotting the
mean CT versus the DNA concentration. Semilogarithmic
plots of CT versus DNA content exhibited R
2 values of
0.997, 0.985, 0.999, and 0.998 for the separate standard
curves.
Linearity of the porcine DNA standard curve was
determined in a manner similar to that used for the ruminant
DNA linearity determination. The R
2 values for four
separate porcine DNA standard curves were 0.998, 0.995,
0.996, and 0.988.
All ruminant DNA standard curves and the porcine
standard curves met the target criterion of R
2≥0.90. No
curvature or trends were observed. The linear correlation
results combined with the visual inspection of the standard
curve residual values demonstrated that the analytical
method met the target linearity for both ruminant and
porcine DNA analysis.
Forward primer: 5’-TCC ATG AGG ATG CAG ATT CAA TCC 
Reverse primer: 5’-CCA CAG CCA CAG CAA CAC 
Internal probe: 5’-FAM-ATC CGA GCC GCA TCT G-NFQ 
Fig. 2 Porcine primers and probe
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Accuracy was determined across the range of the analytical
method by spiking a crude heparin sample prior to
heparinase digestion with known amounts of ruminant
DNA at concentrations of 0.1, 1.0, 200, and 1,000 pg/μL.
Instrument sensitivity and the logarithmic nature of PCR,
which has been previously reported [13], were considered
in the design of an acceptance criterion for accuracy. The
nonlinear response of PCR and the ability of the instrument
to distinguish a twofold to fourfold difference in target
DNA content justified a spike recovery acceptance criterion
of ±0.6 log of the theoretical response. The acceptance
criterion was derived from the logarithm of 4 (i.e., fourfold
sensitivity of the target DNA), which is 0.6. The results
obtained with ruminant DNA and ruminant primers and
probe are shown in Table 1.
Porcine DNA is expected to be present in crude heparin
of porcine origin. The quantitation of porcine DNA in crude
heparin therefore serves as an internal control demonstrat-
ing that the sample has not been adulterated or otherwise
compromised as to alter the response of DNA in the
analytical method. Additionally, the quantitative recovery
of a porcine DNA spike from the crude heparin sample
demonstrates that the sample does not exhibit matrix
interference effects on the analytical method. To determine
the accuracy of the porcine DNA quantitation in crude
heparin, three separate crude heparin samples were spiked
with 200 pg/μL of porcine DNA prior to heparinase
digestion and analyzed. The results obtained with porcine
DNA and porcine primers and probe are shown in Table 1.
The analytical method exhibited appropriate accuracy for
the quantitation of ruminant DNA and porcine DNA by
meeting the target criteria.
Precision
The repeatability of the ruminant quantitative PCR analyt-
ical method was assessed by spiking a crude heparin
sample prior to heparinase digestion with ruminant DNA
at 0.1, 1.0, 200, and 1,000 pg/μL and assaying each sample
in triplicate in three repeated analyses. The relative standard
deviation (RSD) was 1% for all sample analyses, including
the unspiked crude heparin sample.
The repeatability of the porcine quantitative PCR
analytical method was assessed in a similar manner, except
a crude heparin sample was spiked with porcine DNA at
only one concentration (i.e., 200 pg/μL). The samples were
analyzed in triplicate in four repeated analyses, and the
RSD was 1% or less for each analysis.
The target criterion for precision (repeatability) was 10%
or less RSD. The analytical method exceeded the target
criteria for both ruminant and porcine DNA and was
determined to exhibit acceptable repeatability.
The intermediate precision of the ruminant DNA
analytical method was assessed by spiking a crude heparin
sample and heparinase digestion buffer with ruminant DNA
at 0.1, 1.0, 200, and 1,000 pg/μL and assaying each sample
in triplicate on three separate days by two different analysts.
The pooled RSD (n=9) for the spiked heparin sample and
spiked heparinase buffer was 4% or less at all concen-
trations and for both sample types.
The intermediate precision of the porcine DNA analyt-
ical method was assessed in a manner similar to that for the
ruminant DNA analysis, except the crude heparin sample
and heparin digestion buffer were spiked with porcine DNA
at only one concentration (i.e., 200 pg/μL) before the
samples were analyzed in triplicate on four separate days by
two analysts. The pooled RSD (n=12) for the porcine-
DNA-spiked crude heparin sample and for the spiked
digestion heparinase digestion buffer was 3% or less for
both sample types.
These results meet the target criterion of a pooled RSD
of 10% or less and it was determined that the analytical
method exhibited acceptable intermediate precision.
Quantitation limit
The quantitation limit of the analytical method was defined
as the lowest DNA spike concentration in crude heparin
that achieved the acceptance criterion for accuracy of ±0.6
log spike recovery, precision of 10% or less RSD, and fell
within the linear response of the analytical method. As
shown by the previous data, the quantitation limit was
Spike quantity
(pg/uL)
Source Recovery acceptance
criteria (pg/uL)
Recovery (%) Recovery (%) Recovery (%)
(Lot A) (Lot B) (Lot C)
0.1 Ruminant 0.02–0.50 90 350 280
1 Ruminant 0.2–5.0 90 210 120
200 Ruminant 40–1,002 79 122 115
200 Porcine 40–1,002 96 117 71
1,000 Ruminant 200–5,012 59 56 75
Table 1 Recovery of spiked
ruminant and porcine DNA
from crude heparin
760 S.P. Concannon et al.determined to be 0.1 pg DNA/μL for both ruminant and
porcine DNA in crude heparin. When the sample prepara-
tion procedure is taken into consideration, this limit
corresponds to 0.3 ppm ruminant or porcine DNA in crude
heparin powder.
Detection limit
Bovine serum albumin (BSA) may be included as a
stabilizer for both DNA polymerase and heparinase. Both
enzymes are used in the analytical procedure; therefore, a
background response in the NTC and the SEC is expected
owing to trace levels of ruminant DNA associated with
BSA. SEC replicates contained all reagents used during the
analysis, including heparinase and DNA polymerase,
whereas the NTC contained only heparinase digestion
buffer and DNA polymerase. During these experiments
the CT from the SEC was always lower than that from the
NTC, suggesting the presence of minute, yet detectable
quantities of ruminant DNA in the heparinase. The presence
of ruminant DNA in the reagents could not be controlled,
and has the potential of changing between reagent lots. This
observation represents a limitation of this method. On the
basis of statistical analysis and visual examination of the
data, it was difficult to discern the 0.01 pg/μL (i.e.,
0.03 ppm) ruminant DNA response from the background
routinely. Consequently, in practice the quantitation limit
0.1 pg/μL (i.e., 0.3 ppm ruminant DNA in crude heparin)
was also assigned as the detection limit. A detection limit of
0.3 ppm ruminant DNA is comparable to other reported
detection limits for similar analytical methods [6].
Discussion
The identity of the animal origin of crude heparin must be
determined to ensure the safety of the supply chain when
the introduction of transmissible spongiform encephalopa-
thy is a possibility. Quantitative PCR is an ideal tool for this
purpose.
The analytical method described has been developed to
ensure that precautions are taken to avoid a false-negative
response. Heparin, a highly charged glycosaminoglycan, is
well known to inhibit the PCR analysis. The concentration
of crude heparin in the test sample (0.03%) was shown
during development to not inhibit the PCR analysis. A
heparinase digestion step was added to the sample
preparation scheme to degrade the heparin in the sample
and ensure that the heparin in the sample did not inhibit the
quantitative PCR amplification step. Although exogenous
template control DNA may be used as an internal positive
control to assess sample inhibition [10, 14], an authentic
ruminant DNA spike was chosen to evaluate sample
inhibition in the assay described in this evaluation. The
ruminant spike was added to each test sample prior to
heparinase digestion and a recovery criterion was applied to
the spike to verify that accurate results were obtained for all
samples during routine analysis. The inclusion of an
authentic spike of the analyte mitigates the potential effect
of differences in amplification efficiency and experimental
bias that may occur between a commercially available
internal positive control and the target amplicon. Addition-
ally, this strategy eliminates the possibility of a false
negative due to DNase digestion that may occur during
the heparin digestion step. The technique of inhibitor-
controlled PCR previously described [14] incorporates a
semiauthentic internal control which is coamplified in an
end-point PCR analytical method and followed by agarose
electrophoresis. Although this approach eliminates poten-
tial concerns of amplification efficiency between the
control and the target analyte, the construction of the
inhibitor-controlled PCR control is relatively laborious
and the reliance on electrophoresis for detection requires
semiquantitive and subjective analysis. Authentic bovine
DNA and porcine DNA were chosen as the spike for the
positive sample controls in the analytical method to
ensure the specificity and sensitivity of the PCR were
adequately controlled using the specified analyte. Incor-
poration of the ruminant and porcine spikes prior to
heparinase digestion further reduces the possibility of a
false-negative result caused by the presence of DNases in
the crude heparin sample. It is also noteworthy that the
detection and quantitation limits of this method for
ruminant DNA are the lowest reported limits to date in
crude heparin [10, 14]
The analytical method was validated for specificity,
linearity, accuracy, precision (repeatability and intermediate
precision), and quantitation limit. The ruminant DNA
primers and probe were found to amplify bovine, ovine,
and caprine DNA in a quantitative manner and did not
detect porcine DNA. The porcine DNA primers and probe
did not amplify ruminant (bovine) DNA. The range of the
analytical method, defined as acceptable accuracy, preci-
sion, and linearity at the extremes of the analyte concen-
tration and points in between, was found to be 0.3–
6,667 ppm DNA in crude heparin for both ruminant and
porcine DNA. The method described herein has been used
to successfully assess commercial crude heparin since
2005, indicating the stability of the analytical method and
its value to the industry.
Acknowledgements The authors wish to acknowledge Kevin Rust
for his work on development of the porcine primers and probe and
initial development of the analytical method and Jerry Davis for
analysis of crude heparin samples in support of this work. The authors
also wish to acknowledge Monika Lorenz and Vladimir Golynskiy for
their review, guidance, and support of this work.
A quantitative PCR method to quantify ruminant DNA in porcine crude heparin 761Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Nader HB, Dietrich CP (1989) In: Lane DA, Lindahl U (eds)
Heparin: chemical and biological properties, clinical applications.
London, Arnold
2. Will RG (199) ACTA Paediatr Suppl 433:28-32
3. Levieux D, Levieux A (2001) J Immunoassay 22:127–145
4. Levieux A, Rivera V, Levieux D (2001) J Immunoassay
Immunochem 22:323–336
5. Levieux A, Rivera V, Levieux D (2001J) Pharm Biomed Anal
27:305–313
6. Momcilovic D, Rasooly A (2000) J Food Prot 63(11):1602–
1609
7. Krcmar P, Rencova E (2000) J Food Prot 64(1):117–119
8. Gizzi G, van Raamsdonk LWD, Baeten V, Murray I, Beben G,
Brambilla G, von Holst C (2003) Rev Sci Tech Off Int Epizoot 22
(1):311–331
9. Mendoza-Romero L, Verkaar ELC, Savelkoul PH, Catsburg A,
Aarts HJM, Buntjer JB, Lenstra JA (2004) J Food Prot 67:550–
554
10. Houiste C, Auguste C, Macrez C, Dereux S, Derouet A, Anger P
(2009) Clin Appl Thromb Hemost 15:50–58
11. Satsangi J, Jewell DP, Welsh K, Bunce M, Bell JI (1994) Lancet
343(8911):1509–1510
12. Walker JA, Hughes DA, Anders JA, Shewale J, Sinha SK, Batzer
MA (2003) Anal Biochem 316:259–269
13. Lovatt A (2002) Rev Mol Biotechnol 82:279–300
14. Huang Q, Yao C-Y, Chen B, Wang F, Huang J-F, Zhang X, Fu W-
L (2006) Mol Cell Probes 20:250–258
762 S.P. Concannon et al.